Drug Use-results survey for Mantle cell lymphoma of Velcade Injection 3mg

Drug Use-results survey for Mantle cell lymphoma of Velcade Injection 3mg - Drug Use-results survey for Mantle cell lymphoma of Velcade Injection 3mg

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027778

Enrollment

Registered

2017-06-19

Start date

2015-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mantle cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with untreated MCL who receive VELCADE (in combination with R-CAP) for the first time.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness(Best assessment result)	—

Countries

Japan

Contacts

Public ContactHirokazu Shirai

Janssen Pharmaceutical K.K Medical Affiars Delivery Unit

hshirai3@ITS.JNJ.com-

Outcome results